In patient-derived xenograft tumors with high gankyrin levels, in vitro and in vivo experiments have demonstrated that c-MYC inhibition synergized with sorafenib and regorafenib effects, which suggests that gankyrin can contribute to drug resistance in HCC [151]. Here, MYC is linked to hepatocellular carcinoma.